News | Proton Therapy | May 02, 2019

Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation

Multiple Flash irradiations delivered at isocenter in IBA Proteus gantry room

Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation

May 2, 2019 – IBA (Ion Beam Applications SA) recently announced the first Flash irradiation in an IBA proton therapy gantry treatment room at the University Medical Centre Groningen (UMCG) in The Netherlands. This novel technique has the potential to enhance the therapeutic window with a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate.

On March 1, 2019, IBA delivered several Flash irradiations at isocenter in one of the two gantry treatment rooms at UMCG in Groningen, The Netherlands. Results obtained with the current IBA Proteus solution are promising, according to the company, and largely exceed the conditions required to obtain the Flash effect with a dose rate up to 200 Gy/sec.

When compared to radiotherapy delivered at conventional dose rates (1 – 7 cGy/sec), the Flash phenomenon seems to appear when irradiation is delivered with a dose superior to 8 Gy and at a dose rate above 33 Gy/sec in a very short time (less than a second). Researchers theorize that irradiation at very high dose rate causes oxygen depletion in tissues, which renders healthy tissue radioresistant, enabling dose escalation to levels that destroy tumor tissues even in high hypoxia. In other words, healthy tissue seems to better withstand this novel method of irradiation, while the tumor has the same level of sensitivity to Flash irradiation as to conventional treatment.

Hans Langendijk, M.D., Ph.D., chair of radiation oncology, University Medical Centre Groningen, said, “Being the first proton therapy center that has treated patients in The Netherlands, we have the vision that the clinical introduction of new and emerging radiation technologies should be more evidence-based. As the pioneer of the model-based approach for selecting patients for proton therapy in The Netherlands, we look forward to better understand the radiobiological effect of Flash irradiation and predict the benefits and outcomes of Flash therapy for patients.”

The Flash irradiation is highlighted in Science Translational Medicine.

Watch the VIDEO: The Role of the Physicist in Proton Therapy

For more information: www.iba-worldwide.com

Related Content

Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...